Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, reported Reuters.

  • The pill is approved in Britain for use in people with mild to moderate COVID-19. Still, it is unknown whether it would work in patients hospitalized with severe illness, researchers of the RECOVERY trial said.
  • The study will compare 800 mg doses of molnupiravir, given twice daily for five days, with standard care for adult patients in hospitals because of COVID-19.
  • Related: Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters.
  • "Adding molnupiravir (to the study) will allow us to study this drug on its own, but also in combination with other COVID-19 treatments," said Peter Horby, joint chief investigator of the trial and Oxford University professor.
  • Related: UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer.
  • Price Action: MRK shares are down 3.14% at $77.47 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.